Pigment epithelium derived factor (PEDF) prevents methyl methacrylate monomer-induced cytotoxicity in H9c2 cells

Li Xin, Tian Han, Jiao Tang, Xiaoyu Wang, Hao Zhang, Hongyan Dong, Kaijin Guo, Zhongming Zhang

Journal of Biomedical Research ›› 2017, Vol. 31 ›› Issue (6) : 512-520.

PDF(453 KB)
PDF(453 KB)
Journal of Biomedical Research ›› 2017, Vol. 31 ›› Issue (6) : 512-520. DOI: 10.7555/JBR.31.20170068
Original Article
Original Article

Pigment epithelium derived factor (PEDF) prevents methyl methacrylate monomer-induced cytotoxicity in H9c2 cells

Author information +
History +

Abstract

Acrylic bone cements are currently the most frequently and extensively used materials in orthopedic implant treatment. However, adverse effects have been described of acrylic bone cement on the cardiovascular system. In the present study, we examined the cytotoxicity of bone cement ingredient methyl methacrylate (MMA) to cardiomyocytes and the potential detoxifying effect of pigment epithelium-derived factor (PEDF) in H9c2 cells. We found that high concentration of MMA (>120 mmol/L) led to necrotic cell death in H9c2 cells. However, MMA at low concentrations (30-90 mmol/L) caused apoptosis. Pretreatment of PEDF prevented MMA-induced cytotoxicity. In addition, PEDF enhanced total superoxide dismutase activities, and decreased MMA-induced production of malonaldehyde. Furthermore, MMA-induced downregulation of Akt activity was suppressed by PEDF. PEDF also increased the levels of peroxisome proliferator activated receptor gamma (PPARg) and lysophosphatidic acids (LPA) through PEDF receptor. These results indicated that PEDF inhibited MMA-induced cytotoxicity through attenuating oxidative stress, activating the phosphatidylinositol 3-kinase (PI3K)/Akt pathway and/or PEDF receptor-LPA-PPARg pathways in H9c2 cells. PEDF may be explored as a candidate therapeutic agent for alleviating bone cement implantation syndrome during orthopedic surgery.

Keywords

pigment epithelium-derived factor / oxidative stress / bone cement / methyl methacrylate

Cite this article

Download citation ▾
Li Xin, Tian Han, Jiao Tang, Xiaoyu Wang, Hao Zhang, Hongyan Dong, Kaijin Guo, Zhongming Zhang. Pigment epithelium derived factor (PEDF) prevents methyl methacrylate monomer-induced cytotoxicity in H9c2 cells. Journal of Biomedical Research, 2017, 31(6): 512‒520 https://doi.org/10.7555/JBR.31.20170068

1 Introduction

Bone cement implantation syndrome (BCIS) is a rare but potentially lethal intra-operative complication during cemented orthopedic surgeries[1]. It is characterized by hypoxia[2], hypotension[34], cardiac arrhythmias[5], increased pulmonary vascular resistance and cardiac arrest[67], resulting in immediate death in 0.1% of the recipients. Although BCIS has been reported for 46 years, the etiology and pathophysiology of BCIS are still not fully clear. Several mechanisms have been proposed, one of which is the release of acrylic resin-based bone cement materials into the circulation following cementation.
Acrylic resin-based bone cements primarily consist of a solid part of a prepolymerized polymethyl methacrylate (PMMA) and a liquid part of methyl methacrylate (MMA). Various studies have shown adverse effects of acrylic bone cement on body. There are potential neurotoxic effects of PMMA during cranioplasty[89]. Bone cement could induce apoptosis and secondary necrosis in osteoblastic cell lines[1011]. Moreover, oxidative stress is a causal factor for cell damage after exposure to bone cement or bone cement ingredients.N-Acetyl cysteine, a well-known antioxidant, could suppress PMMA-induced cell death in rat primary osteoblasts[12]. It is also reported that MMA reduces myocardial contractility in isolated dog heart muscle model[13]. However, the adverse effects of acrylic bone cement at the cellular level in cardiomyocytes are still unknown.
Pigment epithelium-derived factor (PEDF) is a secreted glycoprotein that belongs to the non-inhibitory serpin family group[14]. A body of evidence indicates that PEDF exerts diverse physiologic activities, such as anti-angiogenic, anti-tumorigenic, anti-inflammatory, antioxidant, neurotrophic and neuroprotective properties. PEDF could inhibit hyperglycemia-induced apoptotic cell death via activating phosphatidylinositol 3-kinase (PI3K)/Akt pathway in goat retinal pericytes[15]. In addition, PEDF was able to attenuate hyperglycemia-induced reactive oxygen species (ROS) in pericytes[16].
Although the antioxidant capacity of PEDF has been well studied in many other fields, there are few studies on the potential protective effects of the agent on bone cement extracts-induced cytotoxicity. Thus, the present study was designed to test the cytotoxicity of MMA to cardiomyocytes and the potential protective effects of PEDF on cardiomyocytes.

2 Materials and methods

2.1 Reagents

Anti-p-Akt antibody (#0458), anti-cleaved caspase-3 (#9664), and anti-β-actin (#13E5) antibodies were purchased from Cell Signaling Technology, USA. PPARg (#ab70405) was purchased from Abcam, Inc. (Abcam, Cambridge,UK). Annexin V-FITC/PI Staining Kit was purchased from Roche, Switzerland. Atglistatin (#SML1075), methyl methacrylate monomer (#55909), necrostatin-1 (#N9037), Hoechst33342 (#861405) and 2`,7`-dichlorofluorescin diacetate (DCFH-DA;#D6883) were purchased from Sigma, USA. Superoxide dismutase (SOD; #A001-1) and malonaldehyde (MDA; #A002-1) detection kit were purchased from JIANCHENG Bioengineering Institute, China. Recombinant rat PEDF was synthesized by CUSABIO BIOTECH CO. Ltd, China. Cell Counting Kit (CCK-8) was from Dojindo Molecular Technologies (Kumamoto, Japan).

2.2 Cell culture, PEDF preincubation and MMA treatment procedure

The embryonic rat heart derived H9c2 cells was obtained from the Cell Bank of Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China), and cryopreserved at School of Medicine, Jiangsu University (Zhenjiang, Jiangsu, China). The cells were cultured in DMEM (Hyclone, Thermo, USA) supplemented with 10% fetal bovine serum (Hyclone, Thermo, USA), 50 U/mL penicillin and 50 mg/mL streptomycin at 37°C at an atmosphere of 95% air and 5% CO2. The cells were trypsinized, plated in 96 well plates or cell culture disks for 24 hours, preincubated with or without PEDF(10 nmol/L) for half an hour, and then began to contact with MMA in serum-free DMEM. Then, the cells were collected and washed two times with PBS and then tested by CCK-8 assay and Annexin V-FITC/propidium iodide (PI) staining.

2.3 CCK-8 cell viability assay

H9c2 cells were seeded in 96-well plates at a concentration of 1x104 cells/mL. After treatment, cell viability was detected by using the CCK-8 kit. Absorbance at 450 nm was measured with a microplate reader (BioTek Synergy2, VT). The means of the optical density (OD) measurements from 6 wells of the indicated groups were used to calculate the percentage of cell viability.

2.4 Annexin V-FITC/propidium iodide staining

H9c2 cells were cultured in 24-well plates. After treatment, the cells were washed three times with PBS gently, then 500 mL of cold binding buffer, 5 mL of Annexin V-FITC and 5 mL of propidium iodide (PI) were added to the wells at room temperature in the dark. Nuclei were stained with Hoechst 33342. The sample was observed by a fluorescence microscope system (Olympus, Japan).

2.5 Western blotting analysis

For Western blotting analysis, the cells were solubilized in lysis buffer (100 mmol/L Tris-HCl, 4% SDS, 20% glycerine, 200 mmol/L DTT and protease inhibitors, pH 6.8). The protein concentrations in the supernatants were measured by BCA protein assay. Protein was separated by 10%, 12% or 15% SDS-PAGE and transferred to nitrocellulose membrane (Millipore, USA). After blocking with 5% non-fat milk/PBS-T for 3 hours at room temperature, the membranes were incubated with primary antibodies (dilution of 1:100). Then, fluorescently labeled secondary antibody (Rockland, USA) was added for 1 hour and subsequently scanned by the Odyssey Infrared Imaging System (Li-Cor Biosciences, USA).

2.6 Detection of intracellular ROS production

Intracellular ROS was measured by 2`7`-dichlorofluorescein (DCF). 2`7`-dichlorodihydorofluorescein diacetate (DCFH-DA; Sigma, St. Louis, MO) is cell-permeant. It can enter the cell where intracellular esterases cleave off the diacetate group. The resulting DCFH is retained in the cytoplasm and oxidized to DCF by ROS. After contact with MMA, cells were then washed once with phenol red-free medium, and incubated in 200 mL working solution of DCFH-DA (20 mmol/L) at 37°C for 30 minutes. The cells were observed under a fluorescence microscope (Olympus, Japan). The fluorescence of DCF was monitored at the excitation and emission wavelengths of 485 nm and 530 nm.

2.7 Measurement of total superoxide dismutase (T-SOD) activities and methane dicarboxylic aldehyde (MDA) levels

T-SOD activities and MDA levels were measured using respective detection kits according to the manufacturers' instructions. Data were observed using multi-mode microplate reader (Synergy 2, Bio-Tek, USA).

2.8 Detection of lysophosphatidic acids (LPA) concentration by ELISA

After treatment with MMA, the cell culture medium was collected and, after addition of phenylmethlsulfonyl fluoride (PMSF; 1 mmol/L) as a serine protease inhibitor, was precleared by centrifugation (25 minutes; 13,000 rpm). Samples were transferred to LPA monoclonal antibody-coated plates. The concentration of LPA was determined by sandwich ELISA kit (CEK623Ge, Cloud-Clone Corp, Wuhan China). Plate preparation and assay procedure were performed according to the manufacturer's recommendations using tetramethylbenzidine as a substrate. The absorbance at 455 nm was read with a reference wavelength of 650 nm using an ELISA plate reader.

2.9 Data analysis

Graphical presentation and statistical analysis were made by GraphPad prism version 5.0 software (GraphPad Inc., San Diego CA). Values are expressed as mean±S.E.M. of at least 3 independent experiments. Statistical analysis of the results was carried out using the Student'st-test or one-way analysis of the variance (ANOVA). Statistical significance was determined at P<0.05.

3 Results

3.1 PEDF attenuated MMA-induced cell death in H9c2 cells

To determine the acute effect of MMA on cell survival rate, H9c2 cells were subjected to increasing concentrations of MMA for 2 hours and examined by CCK-8 assay. As shown inFig. 1A, high concentrations of MMA (>120 mmol/L) significantly decreased the cell survival rate. Next, we determined the type of cell death induced by MMA at high concentrations by flow cytometry using Annexin V-FITC /PI and fluorescence staining. We found that exposure to 150 mmol/L MMA for 2 hours significantly increased the number of necrotic cells (Annexin V-FITC-/PI+) compared with control (Fig. 1B and C). However, the number of apoptotic cells induced by 150 mmol/L MMA (Annexin V-FITC+/PI+ or Annexin V-FITC+/PI-) is low, as the same in control group (Fig. 1B). Furthermore, we found that PEDF markedly decreased MMA-induced necrosis (Fig. 1B and C).
Considering the high concentration of MMA (>120 mmol/L) has not been fully confirmed clinically, we further examined the chronic effects of MMA at low concentration on cell survival rate. As shown inFig. 2A, the chronic treatment of 30-90 mmol/L MMA for 24 also significantly decreased cell survival rate in H9c2 cells. Flow cytometry analysis and fluorescence staining data demonstrated that exposure to 75 mmol/L MMA for 24 hours significantly increased the number of apoptotic cells (Annexin V-FITC+/PI+ or Annexin V-FITC+/PI-) compared with controls (Fig. 2B and C). However, there was no change in the number of necrotic cells after exposure to 75 mmol/L MMA, compared with the control group (Fig. 2B). Importantly, we found that PEDF could markedly decrease MMA-induced apoptosis (Fig. 2B and C).
Fig.1 PEDF attenuates necrosis of H9c2 cells induced by high concentrations of MMA.

Full size|PPT slide

Fig.2 PEDF attenuates low concentrations of MMA-induced apoptosis in H9c2 cells.

Full size|PPT slide

3.2 PEDF suppressed MMA-induced oxidative stress in H9c2 cells

To investigate whether the antioxidant activity is part of the mechanisms by which PEDF attenuated MMA-induced cytotoxicity in H9c2 cells, we first used fluorescent probes DCFH-DA to detect the effect of PEDF on ROS production in H9c2 cells. As shown inFig. 3A and 3C, we found that high concentrations of MMA could produce high levels of ROS. Similarly, there were also high levels of ROS production after low concentrations of MMA treatment (Fig. 3B and 3D). Pretreatment with PEDF for half an hour significantly inhibited ROS production (Fig. 3AD). To further verify the effects of PEDF on MMA-induced oxidative stress, MDA levels and T-SOD activity were examined by special detection kits. As shown inFig. 3E and 3F, PEDF could attenuate MMA-induced upregulation of MDA levels. In addition, PEDF could restore the downregulated levels of T-SOD activity induced by MMA. These data suggest that PEDF suppress MMA-induced oxidative stress in H9c2 cells.
Fig.3 PEDF suppresses MMA-induced oxidative stress in H9c2 cells.

Full size|PPT slide

3.3 PEDF blocked MMA-induced apoptosis via regulating the Akt and/or PEDF receptor-LPA-PPARg pathway

To gain further insight into the mechanism by which PEDF attenuated MMA-induced apoptosis in H9c2 cells, we examined the levels of cleaved caspase-3 and Akt phosphorylation by Western blot analysis. As shown inFig. 4A, 75 mmol/L MMA could significantly increase cleaved caspase-3 levels, further demonstrating that MMA induced apoptosis in H9c2 cells. In addition, pretreatment with PEDF could suppress MMA-induced upregulation of cleaved caspase-3. We also found that MMA-induced downregulation of phosphorylated Akt level was significantly inhibited by PEDF. It has been reported that PEDF promotes cell survival by binding to and stimulating PEDF receptor, subsequently inducing phospholipase A2 liberating fatty acids and lysophosphatidic acid (LPA) from phospholipids. LPA could act as a second messeger to activate the PPARg pathway. To investigate whether the PEDF receptor-LPA-PPARg pathway was involved in the protective effect of PEDF, PEDF receptor inhibitor Atglistatin was used in the present study. As shown in Fig. 4C and D, PEDF could enhance the levels of PPARg and LPA. Furthermore, PEDF-induced upregulation of PPARg and LPA levels was suppressed by Atglistatin. These data suggested that PEDF could suppress MMA-induced apoptosis through regulating the Akt or/and PEDF-LPA-PPARg pathways.
Fig.4 PEDF blocks MMA-induced apoptosis via regulating Akt activities in H9c2 cells.

Full size|PPT slide

4 Discussion

Since bone cement was first used in clinics in 1970s, cardiac arrest cases have been reported following the use of MMA[17]. Although new types of bone cement such as calcium phosphate cement or calcium sulfate cement were invented, their low fracture toughness and poor mechanical reliability restrict their applica-tion[1819]. Acrylic bone cement is still irreplaceable in clinics now. With the increased use of acrylic bone cement during current orthopedic implant treatment, the number of BCIS cases is on rise[20]. However, the pathophysiology of BCIS is not entirely clear. Studies have reported that bone cements have toxicity on the body, including the myocardium. Yasudaet al. first reported that MMA monomer caused a dose-dependent decrease in the maximum velocity of shortening and the maximum force development of dog myocardium[13]. Kim et al. further demonstrated that MMA monomer depressed Ca2+ influx through cardiac membrane and depolarization-activated sarcoplasmic reticulum Ca2+ released through whole-cell voltage clamp measurements[21]. Furthermore, studies found that the cytotoxicity of acrylic bone cement is partly attributed to ROS formation, leading to cell death[22]. Consistent with these studies, our present study also found that MMA stimulation could produce high levels of ROS and decrease cell survival rate in H9c2 cells. The mode of cell death by MMA is related to drug concentration, with necrosis occurring with high concentrations and apoptosis with lower concentration and long time treatment. These data suggest that the occurrence of BCIS might be partly due to the cytotoxicity of MMA on cardiomyocytes.
PEDF-R is a transmembrane protein with phospholipase A2 and triglyceride lipase activity[23]. When PEDF binds to and stimulates PEDF receptor (PEDFR), LPA can be liberated from phospholipids to act as signal transducer. It has been reported that LPA can act on PPARg[24]. The activation of PPARg reduces ROS production and suppresses apoptosis and necroptosis[25]. It has been reported that PPARs is a ligand activated transcription factor, which binds to specific DNA response element and then controls the gene expression of antioxidative enzymes[26]. Our previous studies have demonstrated that PEDF attenuates hypoxia-induced apoptosis and necrosis in H9c2 cells via PEDF receptor[27]. In the present study, PEDF was shown to upregulate the levels of LPA and PPARg, and enhance SOD activity. These data suggest that PEDF might protect against MMA-induced cytotoxicity partly through PEDFR-LPA-PPARg pathway.
The serine-threonine kinase Akt is a non-receptor kinase that plays critical roles in cell growth, survival and metabolism[28]. PEDF could increase SOD activity and phosphorylation of Akt to prevent endothelial dysfunction induced by acute ethanol intake. Consistent with these studies, our present study also demonstrated that PEDF could attenuate MMA-induced cytotoxicity and increase SOD activity and Akt phosphorylation. There are also studies indicating that LPA could activate the PI3K/Akt pathway to exert protective effects[29]. Our present study found that PEDF could increase LPA levels and enhance Akt phosphorylation in H9c2 cells[30]. These data suggest that the activation of PI3K/Akt pathway is also involved in the protective effects of PEDF against MMA-induce cytotoxicity.
In conclusion, the present results showed that MMA induced apoptosis at lower doses and necrosis at higher doses in H9c2 cells. Pretreatment of PEDF could provide protection against MMA-induced cytotoxicity. These effects were attributed to the attenuation of MMA-induced oxidative stress and increased Akt activity. These findings suggest that PEDF and vitamin C may be beneficial in improving the therapeutic strategy of BCIS.

References

[1]
Donaldson AJ, Thomson  HE, Harper NJ , Bone cement implantation syndrome[J]. Br J Anaesth, 2009, 102(1): 12–22
Pubmed
[2]
Modig J, Busch  C, Olerud S , Arterial hypotension and hypoxaemia during total hip replacement: the importance of thromboplastic products, fat embolism and acrylic monomers[J]. Acta Anaesthesiol Scand, 1975, 19(1): 28–43
Pubmed
[3]
Clark DI, Ahmed  AB, Baxendale BR , Cardiac output during hemiarthroplasty of the hip. A prospective, controlled trial of cemented and uncemented prostheses[J]. J Bone Joint Surg Br, 2001, 83(3): 414–418
Pubmed
[4]
Urban MK, Sheppard  R, Gordon MA , Right ventricular function during revision total hip arthroplasty[J]. Anesth Analg, 1996, 82(6): 1225–1229
Pubmed
[5]
Parvizi J, Holiday  AD, Ereth MH , The Frank Stinchfield Award. Sudden death during primary hip arthroplasty[J]. Clin Orthop Relat Res, 1999, (369): 39–48
Pubmed
[6]
Byrick RJ, Forbes  D, Waddell JP . A monitored cardiovascular collapse during cemented total knee replacement[J]. Anesthesiology, 1986, 65(2): 213–216
Pubmed
[7]
Duncan JA. Intra-operative collapse or death related to the use of acrylic cement in hip surgery[J]. Anaesthesia, 1989, 44(2): 149–153
Pubmed
[8]
Pikis S, Goldstein  J, Spektor S . Potential neurotoxic effects of polymethylmethacrylate during cranioplasty[J]. J Clin Neurosci, 2015, 22(1): 139–143
Pubmed
[9]
Alvarez Berastegui GR ,  Raza SM ,  Anand VK , Endonasal endoscopic transsphenoidal chiasmapexy using a clival cranial base cranioplasty for visual loss from massive empty sella following macroprolactinoma treatment with bromocriptine: case report[J]. J Neurosurg, 2016, 124(4): 1025–1031
Pubmed
[10]
Ciapetti G, Granchi  D, Savarino L , In vitro testing of the potential for orthopedic bone cements to cause apoptosis of osteoblast-like cells[J]. Biomaterials, 2002, 23(2): 617–627
Pubmed
[11]
Gough JE, Downes  S. Osteoblast cell death on methacrylate polymers involves apoptosis[J]. J Biomed Mater Res, 2001, 57(4): 497–505
Pubmed
[12]
Yamada M, Ogawa  T. Chemodynamics underlying N-acetyl cysteine-mediated bone cement monomer detoxification[J]. Acta Biomater, 2009, 5(8): 2963–2973
Pubmed
[13]
Yasuda I, Iwatsuki  K. Direct effects of acryl bone cement monomer on isolated heart muscle[J]. Tohoku J Exp Med, 1975, 117(1): 93–97
Pubmed
[14]
King GL, Suzuma  K. Pigment-epithelium-derived factor--a key coordinator of retinal neuronal and vascular functions[J]. N Engl J Med, 2000, 342(5): 349–351
Pubmed
[15]
Haribalaganesh R, Sheikpranbabu  S, Elayappan B , Pigment-epithelium-derived factor down regulates hyperglycemia-induced apoptosis via PI3K/Akt activation in goat retinal pericytes[J]. Angiogenesis, 2009, 12(4): 381–389
Pubmed
[16]
Elahy M, Baindur-Hudson  S, Cruzat VF , Mechanisms of PEDF-mediated protection against reactive oxygen species damage in diabetic retinopathy and neuropathy[J]. J Endocrinol, 2014, 222(3): R129–R139
Pubmed
[17]
Hyland J, Robins  RH. Cardiac arrest and bone cement[J]. Br Med J, 1970, 4(5728): 176–177
Pubmed
[18]
Zhang J, Liu  W, Schnitzler V , Calcium phosphate cements for bone substitution: chemistry, handling and mechanical properties[J]. Acta Biomater, 2014, 10(3): 1035–1049
Pubmed
[19]
Tan H, Yang  S, Dai P , Preparation and physical characterization of calcium sulfate cement/silica-based mesoporous material composites for controlled release of BMP-2[J]. Int J Nanomedicine, 2015, 10: 4341–4350
Pubmed
[20]
Singh V, Bhakta  P, Zietak E , Bone cement implantation syndrome: a delayed postoperative presentation[J]. J Clin Anesth, 2016, 31: 274–277
Pubmed
[21]
Kim KJ, Chen  DG, Chung N , Direct myocardial depressant effect of methylmethacrylate monomer: mechanical and electrophysiologic actions in vitro[J]. Anesthesiology, 2003, 98(5): 1186–1194
Pubmed
[22]
Aita H, Tsukimura  N, Yamada M , N-acetyl cysteine prevents polymethyl methacrylate bone cement extract-induced cell death and functional suppression of rat primary osteoblasts[J]. J Biomed Mater Res A, 2010, 92(1): 285–296
Pubmed
[23]
Notari L, Baladron  V, Aroca-Aguilar JD , Identification of a lipase-linked cell membrane receptor for pigment epithelium-derived factor[J]. J Biol Chem, 2006, 281(49): 38022–38037
Pubmed
[24]
Gendaszewska-Darmach E . Lysophosphatidic acids, cyclic phosphatidic acids and autotaxin as promising targets in therapies of cancer and other diseases[J]. Acta Biochim Pol, 2008, 55(2): 227–240
Pubmed
[25]
Abdel-Raheem IT, Omran  GA, Katary MA . Irbesartan, an angiotensin II receptor antagonist, with selective PPAR-gamma-modulating activity improves function and structure of chemotherapy-damaged ovaries in rats[J]. Fundam Clin Pharmacol, 2015, 29(3): 286–298
Pubmed
[26]
Toba H, Miki  S, Shimizu T , The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta[J]. Eur J Pharmacol, 2006, 549(1-3): 124–132
Pubmed
[27]
Wang X, Zhang  Y, Lu P , PEDF attenuates hypoxia-induced apoptosis and necrosis in H9c2 cells by inhibiting p53 mitochondrial translocation via PEDF-R[J]. Biochem Biophys Res Commun, 2015, 465(3): 394–401
Pubmed
[28]
Sussman MA, Völkers  M, Fischer K , Myocardial AKT: the omnipresent nexus. Physiol Rev, 2011, 91(3): 1023–1070
Pubmed
[29]
Riaz A, Huang  Y, Johansson S . G-protein-coupled lysophosphatidic acid receptors and their regulation of AKT signaling[J]. Int J Mol Sci, 2016, 17(2): 215
Pubmed
[30]
Zhuang W, Zhang  H, Pan J , PEDF and PEDF-derived peptide 44mer inhibit oxygen-glucose deprivation-induced oxidative stress through upregulating PPARg via PEDF-R in H9c2 cells[J]. Biochem Biophys Res Commun, 2016, 472(3): 482–488
Pubmed

Acknowledgments

This work was supported by the National Natural Science Foundation of China (81270173), Jiangsu government grant to study abroad (JS-2013-246) and Xuzhou Science and Technology Projects (XZZD-1329).

RIGHTS & PERMISSIONS

2017 2017 by the Journal of Biomedical Research.
PDF(453 KB)

396

Accesses

2

Citations

Detail

Sections
Recommended

/